CBX - China Biotech XYZ

 Accutar Biotech has terminated the clinical trials of AC176, an AR PROTAC therapy, for the treatment of prostate cancer. These decisions came after the termination of a clinical trial of AC682, an ER PROTAC treatment in the phase 1 stage. Homepage of Accutar The clinical trials AC176 is an AR-targeting PROTAC drug candidate discovered by Accutar Biotech. The IND application was cleared by both the China NMPA and the US FDA. The clinical trial (NCT05673109/CTR20223355) was started in China, with the first patient receiving the dose in February 2023. Currently, the study has enrolled eight patients as reported on the clinical trial disclosure website. However, the trial was terminated due to changes in the benefit-risk ratio for the subjects at the end of 2023. No further statements were reported regarding this matter. The phase 1 trial (NCT05241613) in the US has enrolled 28 patients and has been terminated for the same reason as above. The trial stopped enrolling new patients in Octob

  Jing Medicine (和径医药) has submitted the IND application for HJ-002-03, an EGFR-PROTAC, intended for patients with non-small cell lung cancer in China. HJ-002 is the first PROTAC in the IND stage developed by Jing Medicine. https://doi.org/10.1016/j.ejmech.2022.114533 In 2022, Jing Medicine received IND approval for HJM-353 , an EED inhibitor, in both China and the United States, however, no clinical study has been initiated as of yet. In 2021, Jing Medicine filed a patent (WO2022268229) claiming the PROTACs targeting EGFR, ALK, and ROS1.  These CRBN-based PROTACs, designed with Brigatinib analogs that target ALK and EGFR kinases, may offer a potential new approach for treating lung cancer by inducing targeted protein degradation.  Brigatinib and Embodiments in the Patent E95 and E123 demonstrated potent degradation activity, with DC50 values around single-digit nM and achieving over 90% degradation (Dmax) for EGFR-DTC (Del19/T790M/C797S), EGFR-LTC (EGFR L858R/T790M/C797S), and E

  Accutar Biotech  has terminated the phase 1 clinical study (NCT05489679/ CTR20221967 , due to strategy adjustment) of AC682 (AC0682), an orally administrated ERα-PROTAC, in ER-positive breast cancer, with 6 patients enrolled. The trial, which commenced in November 2021 in the United States, is currently active but not recruiting. Alongside AC0682, Accutar has initiated the clinical trial for another ER degrader, AC699, which is currently ongoing. AC682 is positioned as a potential best-in-class, while AC699 is positioned as having the potential to be the best-in-class with broad mutant coverage. The trial of AC699 was initiated exclusively in the United States in December 2022. Accutar Pipeline In April 2022, the IND application of AC682 was cleared by China CDE. Accutar promptly initiated the trial, and the first patient was enrolled in October.  "In the preclinical studies, AC0682 demonstrated potent and selective ERα protein degradation with favorable pharmacological properti